Sponge-supported Cultures of Primary Head and Neck Tumors for an Optimized Preclinical Model

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Jun 5

PMID 29861851

Citations 6

Authors

Amy J C Dohmen

Joyce Sanders

Sander Canisius

Ekaterina S Jordanova

Else A Aalbersberg

Michiel W M van den Brekel

Jacques Neefjes

Charlotte L Zuur

Affiliations

Soon will be listed here.

Abstract

Treatment of advanced head and neck cancer is associated with low survival, high toxicity and a widely divergent individual response. The sponge-gel-supported histoculture model was previously developed to serve as a preclinical model for predicting individual treatment responses. We aimed to optimize the sponge-gel-supported histoculture model and provide more insight in cell specific behaviour by evaluating the tumor and its microenvironment using immunohistochemistry. We collected fresh tumor biopsies from 72 untreated patients and cultured them for 7 days. Biopsies from 57 patients (79%) were successfully cultured and 1451 tumor fragments (95.4%) were evaluated. Fragments were scored for percentage of tumor, tumor viability and proliferation, EGF-receptor expression and presence of T-cells and macrophages. Median tumor percentage increased from 53% at day 0 to 80% at day 7. Viability and proliferation decreased after 7 days, from 90% to 30% and from 30% to 10%, respectively. Addition of EGF, folic acid and hydrocortisone can lead to improved viability and proliferation, however this was not systematically observed. No patient subgroup could be identified with higher culture success rates. Immune cells were still present at day 7, illustrating that the tumor microenvironment is sustained. EGF supplementation did not increase viability and proliferation in patients overexpressing EGF-Receptor.

Citing Articles

In Vitro Models of Head and Neck Cancer: From Primitive to Most Advanced.

Arutyunyan I, Jumaniyazova E, Makarov A, Fatkhudinov T J Pers Med. 2023; 13(11).

PMID: 38003890 PMC: 10672510. DOI: 10.3390/jpm13111575.

Patient-derived three-dimensional culture techniques model tumor heterogeneity in head and neck cancer.

Parikh A, Yu V, Flashner S, Okolo O, Lu C, Henick B Oral Oncol. 2023; 138():106330.

PMID: 36773387 PMC: 10126876. DOI: 10.1016/j.oraloncology.2023.106330.

Making In Vitro Tumor Models Whole Again.

Wu K, Adine C, Mitriashkin A, Aw B, Iyer N, Fong E Adv Healthc Mater. 2023; 12(14):e2202279.

PMID: 36718949 PMC: 11469124. DOI: 10.1002/adhm.202202279.

Modern Approaches to Testing Drug Sensitivity of Patients' Tumors (Review).

Druzhkova I, Shirmanova M, Kuznetsova D, Lukina M, Zagaynova E Sovrem Tekhnologii Med. 2021; 12(4):91-102.

PMID: 34795997 PMC: 8596271. DOI: 10.17691/stm2020.12.4.11.

Precision Medicine Gains Momentum: Novel 3D Models and Stem Cell-Based Approaches in Head and Neck Cancer.

Affolter A, Lammert A, Kern J, Scherl C, Rotter N Front Cell Dev Biol. 2021; 9:666515.

PMID: 34307351 PMC: 8296983. DOI: 10.3389/fcell.2021.666515.

References

Mery B, Rancoule C, Guy J, Espenel S, Wozny A, Battiston-Montagne P . Preclinical models in HNSCC: A comprehensive review. Oral Oncol. 2017; 65:51-56. DOI: 10.1016/j.oraloncology.2016.12.010. View

Rose Ragin C, Reshmi S, Gollin S . Mapping and analysis of HPV16 integration sites in a head and neck cancer cell line. Int J Cancer. 2004; 110(5):701-9. DOI: 10.1002/ijc.20193. View

Furukawa T, Kubota T, Hoffman R . Clinical applications of the histoculture drug response assay. Clin Cancer Res. 1995; 1(3):305-11. View

Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A . Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol. 2006; 43(8):749-56. DOI: 10.1016/j.oraloncology.2006.09.003. View

Ereno C, Gaafar A, Garmendia M, Etxezarraga C, Bilbao F, Lopez J . Basaloid squamous cell carcinoma of the head and neck: a clinicopathological and follow-up study of 40 cases and review of the literature. Head Neck Pathol. 2010; 2(2):83-91. PMC: 2807543. DOI: 10.1007/s12105-008-0045-6. View

Schmitz S, Machiels J . Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck. Curr Treat Options Oncol. 2016; 17(7):37. DOI: 10.1007/s11864-016-0412-6. View

Dollner R, Granzow C, Helmke B, Ruess A, Schad A, Dietz A . The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma. Anticancer Res. 2004; 24(1):325-31. View

Pignon J, Le Maitre A, Maillard E, Bourhis J . Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92(1):4-14. DOI: 10.1016/j.radonc.2009.04.014. View

Singh B, Li R, Xu L, Poluri A, Patel S, Shaha A . Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck. 2002; 24(5):437-42. DOI: 10.1002/hed.10066. View

10.

Shapiro J, Shapiro W . The subpopulations and isolated cell types of freshly resected high grade human gliomas: their influence on the tumor's evolution in vivo and behavior and therapy in vitro. Cancer Metastasis Rev. 1985; 4(2):107-24. DOI: 10.1007/BF00050691. View

11.

Maiti G, Mondal P, Mukherjee N, Ghosh A, Ghosh S, Dey S . Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes. PLoS One. 2013; 8(5):e63440. PMC: 3651136. DOI: 10.1371/journal.pone.0063440. View

12.

LEIGHTON J . A sponge matrix method for tissue culture; formation of organized aggregates of cells in vitro. J Natl Cancer Inst. 1951; 12(3):545-61. View

13.

Hoffman R . In vitro sensitivity assays in cancer: a review, analysis, and prognosis. J Clin Lab Anal. 1991; 5(2):133-43. DOI: 10.1002/jcla.1860050211. View

14.

Robbins K, Connors K, Storniolo A, Hanchett C, Hoffman R . Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. Arch Otolaryngol Head Neck Surg. 1994; 120(3):288-92. DOI: 10.1001/archotol.1994.01880270036007. View

15.

van Monsjou H, van Velthuysen M, van den Brekel M, Jordanova E, Melief C, Balm A . Human papillomavirus status in young patients with head and neck squamous cell carcinoma. Int J Cancer. 2011; 130(8):1806-12. DOI: 10.1002/ijc.26195. View

16.

Leess F, Bredenkamp J, Lichtenstein A, Mickel R . Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas. Laryngoscope. 1989; 99(12):1255-61. DOI: 10.1288/00005537-198912000-00009. View

17.

Stausbol-Gron B, Nielsen O, Moller Bentzen S, Overgaard J . Selective assessment of in vitro radiosensitivity of tumour cells and fibroblasts from single tumour biopsies using immunocytochemical identification of colonies in the soft agar clonogenic assay. Radiother Oncol. 1995; 37(2):87-99. DOI: 10.1016/0167-8140(95)98589-d. View

18.

Mroz E, Tward A, Tward A, Hammon R, Ren Y, Rocco J . Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas. PLoS Med. 2015; 12(2):e1001786. PMC: 4323109. DOI: 10.1371/journal.pmed.1001786. View

19.

SHERWIN R, Richters A, Yellin A, DONOVAN A . Histoculture of human breast cancers. J Surg Oncol. 1980; 13(1):9-20. DOI: 10.1002/jso.2930130103. View

20.

Janik K, Popeda M, Peciak J, Rosiak K, Smolarz M, Treda C . Efficient and simple approach to in vitro culture of primary epithelial cancer cells. Biosci Rep. 2016; 36(6). PMC: 5146827. DOI: 10.1042/BSR20160208. View